BNET Industries

Inovio Biomedical Corp.

(INO) is in the Health Care Industry

Market Cap:$160.3M
Last Fiscal Year Sales:$4.8M
  • Public
  • US
Dow Jones Description

Inovio Biomedical (AMEX:INO) is focused on developing multiple DNA-based immunotherapies. Inovio is a leader in developing human applications of electroporation, using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Interim human data has shown that Inovio's DNA delivery technology can significantly increase gene expression and immune responses from DNA vaccines. Immunotherapy partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer Institute, and International Aids Vaccine Initiative. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. The company changed it's name from Genetronics Biomedical Corporation in 2001.

Chief Executive Officer
J. Joseph Kim
Number of Employees 37
Contact Information

11494 Sorrento Valley Road

San Diego, California 92121-1318

www.inovio.com

(858) 597-6006

NAICS Code Surgical and Medical Instrument Manufacturing: 339112

Recent Events

  • Emerging Stock Report Initiates Independent Research Coverage on Inovio Biomed Corp

    11/20/09 - Bond / Stock Rating - View Story

  • Therapeutic DNA Vaccine Company Inovio Biomedical Reports Third Quarter 2009 Financial Results

    11/16/09 - Joint Venture / Alliance - View Story

  • Therapeutic DNA Vaccine Company Inovio Biomedical Reports Third

    11/16/09 - Joint Venture / Alliance - View Story

  • Inovio Biomedical Releases 3Q 2009 Financial Results

    11/19/09 - Financial Announcement - View Story

  • Inovio Biomedical CEO Introduces DNA Vaccine Potential at 2009 World Knowledge Forum

    10/13/09 - Product Announcement - View Story

  • Inovio Biomedical, National Microbiology Laboratory, and University of Pennsylvania to Evaluate Candidate DNA Vaccines a

    8/29/09 - Joint Venture / Alliance - View Story

  • Therapeutic DNA Vaccine Company Inovio Reports Second Quarter 2009 Financial Results

    8/23/09 - Joint Venture / Alliance - View Story

  • Company and People Notes: Forest Labs and AstraZeneca Form Pact; Endo COO Resigns; More...

    8/19/09 - Joint Venture / Alliance - View Story

  • Inovio Biomedical, National Microbiology Laboratory, and University of Pennsylvania to Evaluate Candidate DNA Vaccines against...

    6/30/09 - Joint Venture / Alliance - View Story

  • Vaccine Pioneer Joins Inovio Biomedical's Scientific Advisory Board

    6/24/09 - Merger / Acquisition - View Story

  • Vaccine Pioneer Joins Inovio Biomedical’s Scientific Advisory Board

    6/24/09 - Board Member - Entering - View Story

  • Inovio Biomedical Corporation INO Closes Merger with VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.)...

    6/02/09 - Joint Venture / Alliance - View Story

  • Inovio Biomedical to Present at 8th Annual Needham Life Sciences Conference

    6/04/09 - Merger / Acquisition - View Story

News & Analysis

inovio biomedical corp. - All News and Analysis

Decision Makers

Name (plus bio) Position
J. Joseph Kim Chief Executive Officer
Dr. Avtar Dhillon President
C Jo White Chief Medical Officer
Peter Kies CFO
Dietmar P. Rabussay Vice President, Res & Development
George McHugh Vice President, Operations
Iacob Mathiesen Vice President, Research & Development
Robert Goodenow Vice President, Corp Development
Walter Singleton Vice President, Clinical & Regulatory Affairs
Michael Fons Executive Director, Corp Development
Paul M. Goldfarb Director
Arlene A Forastiere
Hubert T Greenway
John Thompson
Kevin W. Rassas Senior Vice President, Business Development
Niranjan Y Sardesai Senior Vice President, Research & Development
Robert S Warren

Board of Directors

Name (plus bio) Position
Felix Theeuwes Board of Directors
Gene Larson Board of Directors
James L. Heppell Board of Directors
Riaz Bandali Board of Directors
Simon X. Benito Board of Directors
Tazdin Esmail Board of Directors

Organization Position Status
Inovio Biomedical Corp. Chief Executive Officer Current
Vgx Pharmaceuticals Inc. Co-Founder, President and CEO Former
Wharton Graduate School of the University of Pennsylvania MBA In Finance Former

Organization Position Status
Inovio Biomedical Corp. President Current
Inovio Biomedical Corp. Board of Directors Current
Protox Therapeutics Inc. Director Current
Inovio Biomedical Corp. Chief Executive Officer Former
TSX Group, Inc. consultant Former
University of British Columbia M.D. Degree Former
University of British Columbia Bachelor of Science Degree In Physiology Former

Organization Position Status
Inovio Biomedical Corp. Chief Medical Officer Current
Vgx Pharmaceuticals Inc. Chief Medical Officer Former
Baylor College of Medicine M.D. Former

Organization Position Status
Inovio Biomedical Corp. CFO Current
Inovio Biomedical Corp. Board of Directors Current
Newgen Results Corporation Chief Financial Officer Former
Ernst & Young Chief Financial Officer Former
United States International University B.S. in Business Administration Former

Organization Position Status
Inovio Biomedical Corp. Vice President, Res & Development Current

Organization Position Status
Inovio Biomedical Corp. Vice President, Operations Current
Integra LifeSciences Holdings Corporation General Manager Former

Organization Position Status
Inovio Biomedical Corp. Vice President, Research & Development Current

Organization Position Status
Inovio Biomedical Corp. Vice President, Corp Development Current

Organization Position Status
Inovio Biomedical Corp. Vice President, Clinical & Regulatory Affairs Current

Organization Position Status
Inovio Biomedical Corp. Executive Director, Corp Development Current

Organization Position Status
Inovio Biomedical Corp. Director Current

Organization Position Status
Inovio Biomedical Corp. Current
University of Michigan Senior Investigator Former

Dr. Hubert Greenway, Jr. was Fellowship trained by Frederic E. Mohs, M.D. at the University of Wisconsin. He has been the director of the Mohs Surgery Unit at Scripps Clinic since 1984 and has performed over 12,000 Mohs Surgery cases for skin cancers of all types. He is also the Director of Cutaneous Oncology, Director of the Melanoma Center and is active in clinical trials and research. He was the first physician to treat Basal Cell Carcinoma and has himself trained a number of physicians in the United States and abroad. Currently, he is serving as secretary for the American College of Mohs Surgery and Cutaneous Oncology and is a member of many local, national and international organizations. Winner of many awards, he currently is and has been listed in "The Best Doctors in America", chosen by recommendations from physicians throughout the United States. He is the author of over 50 publications, including two textbooks and was the Editor in Chief for the Yearbook of Dermatologic Surgery (1997 Ed.).

Organization Position Status
Scripps Clinic Director of the Mohs Surgery Unit Current
Inovio Biomedical Corp. Current
Glg Life Tech Ltd Board of Directors Current
Scripps Clinic CEO Emeritus Former

Organization Position Status
Inovio Biomedical Corp. Current

Organization Position Status
Inovio Biomedical Corp. Senior Vice President, Business Development Current
Vgx Pharmaceuticals Inc. Senior Vice President, Business Development Former
Viral Genomix, Inc Senior Vice President, Business Development Former
Kellogg School of Management at Northwestern University Mba In Finance Former
University of Notre Dame Bachelor of Arts In Economics Former

Organization Position Status
Inovio Biomedical Corp. Senior Vice President, Research & Development Current
Vgx Pharmaceuticals Inc. Senior Vice President, Research Development Former
Wharton Graduate School of the University of Pennsylvania MBA Former
Indian Institute of Technology Former

Organization Position Status
Inovio Biomedical Corp. Current
Surgical Oncology, Inc. Chief Former
New England Journal of Medicine Ad Hoc Reviewer Former
UCSF Medical Center Former
University of Minnesota MD Former

Felix Theeuwes, D.Sc. is Chairman, co-founder, and Chief Scientific Officer at DURECT Corporation, established in July of 1998 as a spinout from ALZA Corporation to focus on the development of pharmaceutical systems and products to treat chronic debilitating diseases and enabling biotechnology drugs. Dr. Theeuwes was with ALZA Corporation from 1970 until June 1999 holding positions directing research, technology development, and product development for a variety of controlled drug delivery systems. His work led to the product introduction of the ALZET® mini osmotic pump series for animal research, and the OROS® systems series of products. He directed research in transdermal research and development, initiated the electrotransport/iontophoresis program, and initiated the DUROS® osmotic implant program. He holds more than 210 U.S. patents covering these systems and published more than 80 articles and book chapters. In 1980 Dr. Theeuwes was named Inventor of the Year by the Peninsula Patent Law Association. In 1983 he was the recipient of the Award for the Advancement of Industrial Pharmacy. He was the Busse Lecturer at the University of Wisconsin in 1981, and in 1985 the Third Annual Sidney Riegelman Lecturer at the University of California, San Francisco. He is a Fellow of the American Association of Pharmaceutical Scientists. In 1993 he became the first recipient of ALZA Corporation's Founder's Award. In 1993 Dr. Theeuwes completed the Stanford Executive Program (SEP). He received his undergraduate and graduate education in physics at the University of Leuven (Louvain), Belgium, with a D.Sc. degree in 1966. From 1966 to 1970 he served as a post-doctoral fellow and visiting research assistant professor in the Department of Chemistry, University of Kansas.

Organization Position Status
DURECT Corporation Chairman & Chief Scientific Officer Current
DURECT Corporation Co-Founder Current
American Association of Pharmaceutical Scientists Fellow Current
Inovio Biomedical Corp. Board of Directors Current
ALZA Corporation Founder Former
University of Kansas Fellow Former
University of California, San Francisco Lecturer Former
The University of Kansas visiting research assistant professor Former
DURECT Corporation Board of Directors Former
University of Leuven D.Sc Former
Antigenics Inc. member Former

Organization Position Status
Inovio Biomedical Corp. Board of Directors Current
UST Inc. CEO Former
Johnson & Johnson senior executive Former
UST Inc. Chairman Former

Organization Position Status
Inovio Biomedical Corp. Board of Directors Current
University of British Columbia Bachelor of Science degree in Microbiology Former

Organization Position Status
Inovio Biomedical Corp. Board of Directors Current

Organization Position Status
Inovio Biomedical Corp. Board of Directors Current
Merck & Co. Inc. Senior Vice President, Merck Vaccine Division Former

Organization Position Status
Inovio Biomedical Corp. Board of Directors Current
Forbes Medi-Tech Inc. Chief Executive Officer Former
Forbes Medi-Tech Inc. President Former
QLT, Inc. Vice President of operations Former

Executive News

  • Inovio Biomedical H1N1 Influenza DNA Vaccines Demonstrate 100% Responses Against Swine Flu in...

    Forbes.com - 7/13/09 - View Story

  • Inovio Biomedical, National Microbiology Laboratory, and University of Pennsylvania to Evaluate Candidate DNA Vaccines against Swine Influenza A (H1N1)

    Business Wire - 6/30/09 - View Story

  • Vaccine Pioneer Joins Inovio Biomedical's Scientific Advisory Board

    Pharma Live - 6/24/09 - View Story

  • Vaccine Pioneer Joins Inovio Biomedical’s Scientific Advisory Board

    Freshnews.com - 6/24/09 - View Story

  • Vaccine Pioneer Joins Inovio Biomedical's Scientific Advisory Board

    Street Insider - 6/24/09 - View Story

  • Vaccine Pioneer Joins Inovio Biomedicals Scientific Advisory

    Business Wire via MSN Money - 6/24/09 - View Story

  • Vaccine Pioneer Joins Inovio Biomedical's Scientific Advisory Board

    RBC Dain Raushcer - 6/24/09 - View Story

  • Vaccine Pioneer Joins Inovio Biomedicals Scientific Advisory Board

    Business Wire - 6/24/09 - View Story

advertisement
Click Here
     INO $1.57 +0.04 (2.61% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 1,717,960
Shares Outstanding 102.13M
Market Cap 160.3M
Year High 3.4
Year Low 0.17
Earnings Per Share -0.39
P/E Ratio -4.03
Dividend N/A
Yield N/A
IndustryTop Rated
advertisement